{"id":3319,"date":"2026-09-21T09:00:00","date_gmt":"2026-09-21T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3319"},"modified":"2026-09-21T20:18:19","modified_gmt":"2026-09-22T00:18:19","slug":"oral-stat6-degrader-bcr-0008-clears-china-clinical-entry","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3319","title":{"rendered":"Oral STAT6 Degrader BCR-0008 Clears China Clinical Entry"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Hangzhou Baicreat<\/p>\n

Event Type<\/strong><\/p>\n

Regulatory Clinical Clearance (NMPA CDE)<\/p>\n

Modality<\/strong><\/p>\n

Oral PROTAC (Targeted Protein Degrader)<\/p>\n

Asset<\/strong><\/p>\n

BCR-0008<\/p>\n

Target<\/strong><\/p>\n

STAT6<\/p>\n

Disease Area<\/strong><\/p>\n

Atopic Dermatitis and Asthma (Type 2 Inflammatory Disease)<\/p>\n

Summary<\/h4>\n

Hangzhou Baicreat reported that China’s NMPA Center for Drug Evaluation permitted clinical testing of BCR-0008, an oral STAT6-targeted PROTAC intended initially for atopic dermatitis and asthma. The milestone moves targeted protein degradation into a non-oncology transcription factor and inflammatory pathway. All potency, pharmacokinetic, and safety evidence disclosed to date is preclinical and company-reported.<\/p>\n

BCR-0008 was accepted for Chinese IND review on July 13 and reported as approved to begin trials on September 15. The company describes picomolar cellular STAT6 degradation, blockade of IL-4 and IL-13 signaling, oral exposure and tissue distribution, activity in dermatitis and asthma models, and no significant drug-related findings in its preclinical safety package. Numerical datasets and a clinical protocol were not publicly available.<\/p>\n

STAT6 is a transcription factor downstream of IL-4 and IL-13, cytokines already clinically validated by biologics such as dupilumab. A degrader could offer oral administration and catalytic target removal, but must achieve selectivity over related transcriptional programs and adequate tissue exposure while avoiding systemic immune and hematologic effects. CDE permission establishes regulatory entry, not efficacy or competitive superiority.<\/p>\n

Deep Analysis<\/h4>\n

One interpretation is that degrading STAT6 can reproduce broad type 2 inflammation control in an oral small molecule. Target validation from approved antibodies supports pathway relevance, and degradation may overcome challenges of direct catalytic inhibition. Against this, pathway validation does not validate the molecule; chronic systemic STAT6 suppression could alter host defense, immune regulation, and tissue repair.<\/p>\n

A second interpretation is that the platform has solved oral PROTAC liabilities including molecular size, permeability, and metabolic instability. The company reports favorable exposure and distribution, but no audited values or human pharmacokinetic data exist. E3 ligase expression, target resynthesis, and tissue-specific degradation may produce variable pharmacology across skin and lung.<\/p>\n

Company and Product Background<\/h4>\n

Baicreat is a Hangzhou biotechnology company developing medicines for inflammatory and autoimmune diseases using degrader and inhibitor platforms. PROTACs recruit an E3 ubiquitin ligase to a target protein, causing proteasomal destruction. STAT6 transduces IL-4 and IL-13 signals that drive type 2 inflammation in diseases including atopic dermatitis and asthma.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Regulatory milestone: NMPA CDE permission to begin clinical testing, reported September 15, 2026.<\/li>\n
  • Modality: oral PROTAC designed to degrade STAT6, a transcription factor downstream of clinically validated IL-4\/IL-13 biology.<\/li>\n
  • Evidence gap: no human pharmacokinetic, pharmacodynamic, safety, efficacy, protocol, or quantitative preclinical data disclosed.<\/li>\n
  • Upgrade path: a registered dose-escalation protocol, human target degradation in blood and affected tissue, exposure-response data, clean cytokine and infection safety, and clinical activity at practical oral doses.<\/li>\n
  • Falsifier: failure to show human degradation, excessive off-target proteomics, poor bioavailability, or immunologic toxicity.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    This is a strategically novel but directionally uncertain clinical entry. Moving an oral degrader against STAT6 into humans could expand targeted degradation beyond oncology and validate a China-developed platform. The thesis should be judged first on human tissue target engagement and exposure margin, not claims of first-in-class status or preclinical potency.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal importance is moderate-to-high given the novelty of extending targeted degradation into a non-oncology inflammatory transcription factor with clinically validated pathway biology. Direction is uncertain because no human data yet exist. Confidence in the underlying facts is moderate-high, based on the company’s IND acceptance notice and multiple Chinese reports of CDE permission, while confidence in interpretation is low-moderate because the clinical record and quantitative supporting package are not yet public.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Hangzhou Baicreat reported that China’s NMPA Center for Drug Evaluation permitted clinical testing of BCR-0008, an oral STAT6-targeted PROTAC intended initially for atopic dermatitis and asthma. The milestone moves targeted protein degradation into a…<\/p>\n","protected":false},"author":1,"featured_media":3343,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,4],"tags":[183,817,818],"class_list":["post-3319","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-technology-modalities","tag-atopic-dermatitis","tag-baicreat","tag-stat6"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3319","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3319"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3319\/revisions"}],"predecessor-version":[{"id":3344,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3319\/revisions\/3344"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3343"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3319"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3319"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3319"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}